C12N 9/99
Enzyme inactivation by chemical treatment
C12N9/99 (Enzyme inactivation by chemical treatment) appears on 325 US grants and 409 published applications in this corpus.
Search patents in C12N- Granted patents
- 325
- Published applications
- 409
- Assignees
- 296
- Inventors
- 1,180
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 8 | 0 |
| 1981 | 4 | 0 |
| 1982 | 5 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 5 | 0 |
| 1993 | 4 | 0 |
| 1994 | 5 | 0 |
| 1995 | 6 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 3 | 0 |
| 2001 | 6 | 0 |
| 2002 | 3 | 8 |
| 2003 | 4 | 9 |
| 2004 | 4 | 7 |
| 2005 | 3 | 4 |
| 2006 | 7 | 10 |
| 2007 | 0 | 16 |
| 2008 | 7 | 14 |
| 2009 | 3 | 15 |
| 2010 | 3 | 13 |
| 2011 | 10 | 25 |
| 2012 | 15 | 19 |
| 2013 | 17 | 30 |
| 2014 | 25 | 28 |
| 2015 | 32 | 35 |
| 2016 | 20 | 21 |
| 2017 | 16 | 15 |
| 2018 | 18 | 14 |
| 2019 | 9 | 13 |
| 2020 | 13 | 16 |
| 2021 | 11 | 14 |
| 2022 | 8 | 13 |
| 2023 | 4 | 11 |
| 2024 | 7 | 21 |
| 2025 | 9 | 10 |
| 2026 | 2 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inhibitors of SARM112 May 2026US 12,624,025 B2Disarm Therapeutics, Inc.
- Method for predicting sensitivity of cancer cell to GPX4 inhibitor20 Jan 2026US 12,529,701 B2Chugai Seiyaku Kabushiki Kaisha
- Inhibitors for protein n-terminal methyltransferase and uses thereof25 Nov 2025US 12,479,887 B2Purdue Research Foundation
- Inhibitors of RNA-guided nuclease activity and uses thereof4 Nov 2025US 12,460,244 B2The Brigham and Women S Hospital, Inc.
- Anti-PAD4 antibody21 Oct 2025US 12,448,464 B2Pharma Foods International Co., Ltd.
- Methods For Inhibiting Neuronal Degeneration To Preserve Residual Functionality And Enhance Axonal Fusion17 Sep 2026US 2026/0273141 A1
- Methods for Enhanced Gene Expression in Microorganisms10 Sep 2026US 2026/0265675 A1Algae-C Inc.
- Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer27 Aug 2026US 2026/0248806 A1National Cancer Center
- Zak alpha kinase (map3k20) inhibitors for use in the treatment of anemia20 Aug 2026US 2026/0240846 A1
- Use of Inhibitors to Increase Efficiency of CRISPR/Cas Insertions20 Aug 2026US 2026/0242829 A1AstraZeneca AB
Most cited
By later US patents
- Nucleic acid amplification using a reversibly inactivated thermostable enzyme206US 5,773,258 ARoche Molecular Systems, Inc. · 1998
- Nucleic acid amplification using a reersibly inactivated thermostable enzyme169US 5,677,152 ARoche Molecular Systems, Inc. · 1997
- Inhibitors of human phosphatidyl-inositol 3-kinase delta138US 6,949,535 B2ICOS Corporation · 2005
- Inhibitors of human phosphatidylinositol 3-kinase delta135US 6,667,300 B2ICOS Corporation · 2003
- Method for reversible modification of thermostable enzymes76US 6,183,998 B2Qiagen GmbH Max-Volmer-Strasse 4 · 2001